Monitor Japan sales uptake of LEQEMBI Pen and potential reimbursement expansion; the SC formulation may broaden patient access and reduce treatment burden, but no revenue guidance was provided.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $253.40entry
- T+1 · 16h ago −0.69%α +1.22% · $251.65
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Eisai and Biogen launched LEQEMBI Pen, the subcutaneous autoinjector formulation of lecanemab, in Japan following NHI Drug Price listing. This is the second country launch after the U.S., offering once-weekly self-administration to reduce clinic visit burden and healthcare resource use for Alzheimer's disease patients.
Key Facts
- LEQEMBI Pen launched in Japan on Nov 12, 2026, after NHI Drug Price listing at 27,141 JPY per pen.
- Japan is the second country after the U.S. to launch the subcutaneous formulation.
- LEQEMBI Pen is an autoinjector for once-weekly self-administration (500 mg total via two pens).
- SC formulation showed similar exposure to IV and lower injection-related reaction incidence (1.4% vs IV).
- LEQEMBI is approved in 53 countries and regions; SC initiation approved in U.S. (July 2026) and China (Sept 2026).
Financial Impact
No financial terms disclosed; NHI Drug Price set at 27,141 JPY per pen.
Risk Factors
- No financial impact or revenue projections stated in the release.
- Self-administration requires careful patient selection and training; safety monitoring (MRI for ARIA) remains necessary.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402340 |
Track record
34 reports on BIIB
10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Viewing Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers